News

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
About a dozen lawsuits, citing 2024 studies, allege Ozempic causes a rare eye disorder that leads to irreversible blindness. ...
Novo Nordisk (NVO) won a key case Thursday to stop some compounding ... which are supposed to halt selling compounded ...
Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...
Novo Nordisk faces a suit claiming it failed to warn users of Ozempic of the danger of blindness. The suit is brought by a ...
Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...